← 返回

抗肿瘤内异质性基因特征预测乳腺癌预后和免疫浸润

英文原题:Intra-tumor heterogeneity-resistant gene signature predicts prognosis and immune infiltration in breast cancer.

查看英文原题

Intra-tumor heterogeneity-resistant gene signature predicts prognosis and immune infiltration in breast cancer.

PubMed 2025/09/26(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

通过最小化 ITH 干扰,本研究为 BC 开发了一个稳健的预后特征,为肿瘤免疫微环境和潜在治疗策略提供了见解。

中文摘要

乳腺癌(BC)仍严重威胁人类健康,患者预后和治疗应答存在显著差异。肿瘤内异质性(ITH)给开发可靠的预后模型带来关键挑战。

本研究整合了乳腺癌患者多区域RNA测序数据和TCGA乳腺癌数据集。通过评估患者间异质性(IPH)和ITH,筛选对采样偏倚具有耐受性的基因。研究采用包含10种算法的机器学习框架构建预后特征,并通过RT-qPCR和体外实验验证预后基因的表达水平及致癌功能。

由CFL2和SPNS2组成的特征在训练队列和验证队列中均显示稳定的预测表现(C指数>0.6)。高风险患者的免疫浸润更丰富,尤其是CD8⁺ T细胞,免疫检查点分子表达也更高,提示其可能对免疫治疗敏感。将风险评分与临床变量整合的列线图进一步提高了预后准确性。研究还在乳腺癌细胞系中验证了特征基因的表达失调。

通过尽量减少ITH干扰,本研究建立了稳健的乳腺癌预后特征,为理解肿瘤免疫微环境及潜在治疗策略提供了依据。

展开英文摘要原文

Breast cancer (BC) remains a significant threat to human health, with substantial variations in prognosis and treatment responses. Intra-tumor heterogeneity (ITH) presents a critical challenge in developing reliable prognostic models.

This study integrated multi-region RNA sequencing data from BC patients with the TCGA BC dataset. Genes resistant to sampling bias were identified by evaluating inter-patient heterogeneity (IPH) and ITH. A machine learning framework incorporating ten algorithms was used to construct a prognostic signature.The expression levels and oncogenic function of the prognostic genes were validated through RT-qPCR and in vitro experiments.

The signature, comprising CFL2 and SPNS2, demonstrated stable predictive performance in both training and validation cohorts (C-index > 0.6). High-risk patients exhibited enriched immune infiltration, particularly CD8+ T cells, and higher expression of immune checkpoint molecules, suggesting sensitivity to immunotherapy. A nomogram integrating risk score with clinical variables further improved prognostic accuracy. The dysregulation of signature genes was confirmed in BC cell lines.

By minimizing ITH interference, this study developed a robust prognostic signature for BC, offering insights into the tumor immune microenvironment and potential therapeutic strategies.

论文信息

作者
Shen H、Zheng Q、Pan J、Jin Y、Zheng X、Yuan Q、Tan D、Zhou Q
单位
Affiliated Cixi Hospital, Wenzhou Medical University, Ningbo, Zhejiang, China.China
期刊
Frontiers in immunology2025
原文标识
PubMed 41080607 · DOI 10.3389/fimmu.2025.1598858